Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split
November 14 2019 - 12:45PM
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the
commercialization and development of prescription ophthalmology
treatments for the management of retinal diseases, announces that
it has filed a certificate of amendment to its restated certificate
with the Secretary of State of the State of Delaware that will
effect the previously announced one-for-15 reverse stock split of
its common stock. The certificate of amendment provides that
the reverse stock split will become effective at 5:01 PM Eastern
Time today, after the close of trading on The Nasdaq Global Market.
On November 15, 2019, Alimera’s common stock will begin trading on
a post-reverse stock split basis on The Nasdaq Global Market under
the existing symbol “ALIM.”
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that
specializes in the commercialization and development of
prescription ophthalmic pharmaceuticals for the management of
retinal diseases. Alimera is presently focused on diseases
affecting the back of the eye, or retina, because these diseases
are not well treated with current therapies and will affect
millions of people in our aging populations. For more information,
please visit www.alimerasciences.com.
Forward-Looking StatementsThis press release
contains a “forward-looking statement” within the meaning of the
Private Securities Litigation Reform Act of 1995 regarding
Alimera’s expectation that its common stock will trade The Nasdaq
Global Market on a post-reverse stock split basis on November 15,
2019. The forward-looking statement is based on current
expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change this
expectation, and could cause actual results to differ materially
from those projected in the forward-looking statement. Meaningful
factors that could cause actual results to differ include, but are
not limited to, unforeseen technical issues that could result in
Alimera’s common stock not trading on The Nasdaq Global Stock
Market on a post-reverse stock split basis on November 15, 2019 as
expected.For press inquiries:Jules Abrahamfor
Alimera Sciences 917-885-7378julesa@coreir.comFor investor
inquiries:Scott Gordonfor Alimera
Sciencesscottg@coreir.com
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2023 to Apr 2024